Skyline Ventures
This article was originally published in Start Up
Executive Summary
At a time when venture capital is increasingly becoming the domain of very large funds, Skyline Ventures is something of an anomaly; a firm that looks to take health care companies at their infancy and help build them to the point where they can attract major venture backing.
You may also be interested in...
Earlybird Venture Capital LLC
Earlybird hopes to capitalize on the convergence of information technologies with health care. It sees these two sectors not as separate strands with fundamentally different investment strategies, but rather as areas whose increasing overlap presents a new pool of companies needing support with experience in both businesses, and, the contend, bi-continental reach.
AureoGen Biosciences Inc.
Formed by Kalamazoo-based Pharmacia alumni, AureoGen Biosciences Inc. is genetically engineering cyclic peptides to create second-generation, resistance-proof anti-infective and anti-fungal therapeutics.
Pain Therapeutics
Pain seems as close to a sure bet as the pharmaceutical industry has to offer. Forecasts call for the worldwide analgesic market, already $38 billion in 2002, to grow at a 20% annual clip, nearly doubling to $75 billion by the year 2010. For new drug developers, pain also has the advantage of offering clearly definable endpoints-less pain-and a relatively short duration for clinical trials. No surprise then that more than 200 companies have a hand in developing or marketing pain therapeutics. Among them, the three young companies profiled here-AlgoRx Pharmaceuticals Inc., Algos Therapeutics Inc., and TheraQuest Biosciences LLC.